Frankfurt - Delayed Quote EUR
Solasia Pharma K.K. (9SO.F)
0.1680
0.0000
(0.00%)
As of May 13 at 9:48:04 PM GMT+2. Market Open.
Key Executives
Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Yoshihiro Arai | President, CEO & Representative Director | -- | -- | 1960 |
| Mr. Toshio Miyashita | CFO, GM of Management Headquarters & Director | -- | -- | 1967 |
| Yasumitsu Shimada | Accounting Manager | -- | -- | -- |
| Yasuaki Manabe | Head of Marketing Division | -- | -- | -- |
| Fumiko Nagahama | Head of Product Development Division | -- | -- | -- |
| Hikaru Osawa | Head of Production Management Division | -- | -- | -- |
| Wataru Kobayashi | Head of Reliability Assurance Division | -- | -- | -- |
| Kozo Yao | Head of Business Development Division | -- | -- | -- |
Solasia Pharma K.K.
Sumitomo Fudosan Shiba-Koen Tower
4th Floor 2-11-1, Shiba-koen Minato-ku
Tokyo, 105-0011
Japan
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 23
Description
Solasia Pharma K.K. engages in the development and marketing of oncology drugs in Japan and other Asian countries. The company offers Episil, an oral liquid for oral mucositis/stomatitis; DARVIAS, an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma; and Sancuso for chemotherapy induced nausea and vomiting. It also develops SP-04, which is in preclinical trial development to treat chemotherapy peripheral neuropathy; and SP-04, which is in preclinical trial development for the treatment of colorectal cancer. The company was founded in 2006 and is based in Tokyo, Japan.
Corporate Governance
Solasia Pharma K.K.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
May 14, 2025 at 6:30 AM UTC
Solasia Pharma K.K. Earnings Date
Recent Events
Recent Events Information Not Available
Related Tickers
6QC.F Towa Pharmaceutical Co., Ltd.
15.70
0.00%
1MRK.MI Merck KGaA
125.95
+0.64%
3D7.F Willow Biosciences Inc.
0.0190
0.00%
CAIHF Chia Tai Enterprises International Limited
0.0100
0.00%
2WU.F Lowell Farms Inc. R
0.0005
0.00%
0T01.F TILT Holdings Inc.
0.0050
0.00%
8Z1.F PharmaEssentia Corporation
0.0000
-100.00%
4KF0.F Glass House Brands Inc.
3.5800
0.00%
AVCNF Avicanna Inc.
0.1730
0.00%
BSPK Bespoke Extracts, Inc.
0.1023
0.00%